ReviewFrontiers in oncology2024
Radiomics in rectal cancer: current status of use and advances in research.
Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiomic Analysis of MRI for Assessing Response to Neoadjuvant Chemoradiotherapy in Rectal Adenocarcinoma: A Systematic Review and Metaanalysis.Molecular imagingPooled it
- Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management.MedComm · 2026Review
- Integrating CT-Based Radiomics Analysis With Serum CEA Level to Predict Neoadjuvant Chemoradiotherapy Response in Colorectal Cancer.The Kaohsiung journal of medical sciences · 2026Article
- MRI-Based Radiomics to Predict Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer: A Retrospective Study.Journal of personalized medicine · 2026Article
- Diagnostic Performance and Misclassification Patterns of Preoperative MRI in Rectal Cancer: A Real-World Study.Diagnostics (Basel, Switzerland) · 2026Article
- MRI-Based Morphological Features as Predictors of Clinical Outcomes in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy: Insights from a Single-Institution Experience.Journal of clinical medicine · 2026Article
- Comparison of Radiomic Features from Different MRI Sequences for Predicting Synchronous Liver Metastases after Rectal CancerCurrent medical imaging · 2026Article
- The Value of MRI-Based Radiomics in Predicting the Pathological Nodal Status of Rectal Cancer: A Systematic Review and Meta-Analysis.Bioengineering (Basel, Switzerland) · 2025Review
- Neoadjuvant therapy for pMMR/MSS locally advanced rectal cancer in the immunotherapy era: current landscape and future perspectives.Frontiers in oncology · 2025Review
- Diffusion-weighted imaging increases the diagnostic performance of magnetic resonance imaging in assessing rectal cancer T stage and reduces intra- and interobserver variability.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rectal cancer is a leading cause of morbidity and mortality among patients with malignant tumors in China. In light of the advances made in therapeutic approaches such as neoadjuvant therapy and total mesorectal excision, precise preoperative assessment has become crucial for developing a personalized treatment plan. As an emerging technology, radiomics has gained widespread application in the diagnosis, assessment of treatment response, and analysis of prognosis for rectal cancer by extracting high-throughput quantitative features from medical images. Radiomics thus demonstrates considerable potential for optimizing clinical decision-making. In this paper, we reviewed recent research focusing on advances in the use of radiomics for managing rectal cancer. The review covers TNM staging of tumors, assessment of neoadjuvant therapy outcomes, and survival prediction. We also discuss the challenges and prospects for future developments in translational medicine, particularly the need for data standardization, consistent feature extraction methodologies, and rigorous model validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.